BOSTON, July 22, 2022 (GLOBE NEWSWIRE) — PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Caroline Godfrey, Ph.D., one of PepGen’s scientific co-founders, to its Scientific Advisory Board. In connection with this appointment, Dr. Godfrey leaves her position as Senior Vice President of Discovery at PepGen.
“We are delighted that Caroline will continue to contribute to PepGen’s science as part of our Scientific Advisory Board, and we look forward to benefiting from her experience and counsel in the years ahead,” said James McArthur, Ph.D., President and Chief Executive Officer of PepGen. “As we consolidate and expand PepGen’s operations in Boston, this appointment facilitates a continuity of expertise as we strive to develop transformative treatments for neuromuscular and neurological diseases. Caroline is one of our scientific co-founders, and was appointed as the first Chief Executive Officer of PepGen following the company’s spinout from the University of Oxford and the Medical Research Council of United Kingdom Research and Innovation. In this role, and in her later position as Senior Vice President of Discovery, she was instrumental in establishing the company, securing the company’s initial and Series A funding, and leading our early-stage discovery efforts. We are incredibly grateful for all that Caroline has done for PepGen and look forward to her continued contributions.”
Prior to founding PepGen, Dr. Godfrey was a Postdoctoral Researcher focused on the development of novel tools for nucleic acid delivery in neuromuscular disorders before becoming a Project Manager at the University of Oxford. Building off research conducted with Professor Matthew Wood and Dr. Michael Gait, Dr. Godfrey co-Founded PepGen and served as the company’s first Chief Executive Officer. Since January 2021, Dr. Godfrey focused on discovery research as PepGen’s Senior Vice President of Discovery. Dr. Godfrey received her Ph.D. in neuromuscular disease from University College London and received her B.S. in genetics from the University of Sheffield.
“I’m excited to be moving into a new position on PepGen’s Scientific Advisory Board,” said Dr. Godfrey. “I feel very privileged to have had the opportunity to lead the PepGen team during the company’s early stages of development, and to have played a role in advancing our Enhanced Delivery Oligonucleotide (EDO) technology from the bench to the clinic. I look forward to continuing this journey with PepGen as we strive to deliver our EDO therapeutics to patients who so desperately need transformative treatment options."
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” “look forward,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements about our clinical and pre-clinical programs, product candidates, our technology, corporate and clinical/pre-clinical strategies, and Dr. Godfrey’s expected contributions to business in the future.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1 trial for EDO51 and pre-clinical studies of other product candidates and obtain required approval before commercialization; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen’s programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent quarterly report on Form 10-Q to be filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.